Revive Therapeutics Announces Research Collaboration For Natural Psilocybin Biosynthesis
Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a sponsored research collaboration agreement, as well as an exclusive option to license agreement, with that of the North Carolina State University. The arrangements are focused on developing a novel biosynthetic version of psilocybin.
The biosynthetic version of psilocybin is said to be based on a natural biosynthetic enzymatic platform, which was developed by Dr Gavin Williams, a professor at researcher at North Carolina State University. The platform is said to have the potential of providing a “simple and efficient method for rapidly producing natural products, such as psilocybin.”
The tech reportedly works via the use of an engineered enzyme pathway in E. coli. The science is based on the development of an artificial enzymatic platform that has been named the “Alcohol Dependent Hemiterpene,” with the pathway reportedly used as a key building block for psilocybin and its derivatives.
If successful, Revive has identified that it intends to develop and commercialize its own pharma-grade psilocybin with this biosynthesis technology at scale, which will be used to support its current psilocybin-based product pipeline.
“We are excited to partner with NC State and work with Dr. Williams and his team to develop a proprietary form of psilocybin that can be produced at scale for research and commercial purposes while allowing us to create our own unique product offerings with psilocybin in different delivery methods so as to treat the various mental health conditions and other diseases that psilocybin has shown to be a potential viable treatment option for.”
Michael Frank, CEO of Revive
Revive Therapeutics last traded at $0.61 on the CSE.
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
